Clinical trial NCT00389168 - References

Hypertension — Irbesartan and Atenolol in Hypertensive Heart Disease

Citation(s)

•   Jekell A, Malmqvist K, Wallén NH, Mörtsell D, Kahan T
  Markers of inflammation, endothelial activation, and arterial stiffness in hypertensive heart disease and the effects of treatment: results from the SILVHIA study. J Cardiovasc Pharmacol. 2013 Dec;62(
•   Kurland L, Hallberg P, Melhus H, Liljedahl U, Hashemi N, Syvänen AC, Lind L, Kahan T
  The relationship between the plasma concentration of irbesartan and the antihypertensive response is disclosed by an angiotensin II type 1 receptor polymorphism: results
•   Kurland L, Liljedahl U, Karlsson J, Kahan T, Malmqvist K, Melhus H, Syvänen AC, Lind L
  Angiotensinogen gene polymorphisms: relationship to blood pressure response to antihypertensive treatment. Results from the Swedish Irbesartan Left Ventricular Hypertr
•   Liljedahl S, Kahan T, Lind L, Arnlöv J
  The effects of antihypertensive treatment on the doppler-derived myocardial performance index in patients with hypertensive left ventricular hypertrophy: results from the Swedish irbesartan in left ventricular hyper
•   Malmqvist K, Kahan T, Edner M, Bergfeldt L
  Cardiac repolarization and its relation to ventricular geometry and rate in reverse remodelling during antihypertensive therapy with irbesartan or atenolol: results from the SILVHIA study. J Hum Hypertens. 2007
•   Malmqvist K, Kahan T, Edner M, Bergfeldt L
  Comparison of actions of irbesartan versus atenolol on cardiac repolarization in hypertensive left ventricular hypertrophy: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation Versus A
•   Malmqvist K, Kahan T, Edner M, Held C, Hägg A, Lind L, Müller-Brunotte R, Nyström F, Ohman KP, Osbakken MD, Ostergern J
  Regression of left ventricular hypertrophy in human hypertension with irbesartan. J Hypertens. 2001 Jun;19(6):1167-76.
•   Malmqvist K, Ohman KP, Lind L, Nyström F, Kahan T
  Long-term effects of irbesartan and atenolol on the renin-angiotensin-aldosterone system in human primary hypertension: the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (S
•   Mörtsell D, Malmqvist K, Held C, Kahan T
  Irbesartan reduces common carotid artery intima-media thickness in hypertensive patients when compared with atenolol: the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) stu
•   Müller-Brunotte R, Edner M, Malmqvist K, Kahan T
  Irbesartan and atenolol improve diastolic function in patients with hypertensive left ventricular hypertrophy. J Hypertens. 2005 Mar;23(3):633-40.
•   Müller-Brunotte R, Kahan T, López B, Edner M, González A, Díez J, Malmqvist K
  Myocardial fibrosis and diastolic dysfunction in patients with hypertension: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SIL
•   Müller-Brunotte R, Kahan T, Malmqvist K, Edner M; Swedish ibesartan left ventricular hypertrophy investigation vs atenolol (SILVHIA)
  Blood pressure and left ventricular geometric pattern determine diastolic function in hypertensive myocardial hypertrophy
•   Müller-Brunotte R, Kahan T, Malmqvist K, Ring M, Edner M
  Tissue velocity echocardiography shows early improvement in diastolic function with irbesartan and atenolol therapy in patients with hypertensive left ventricular hypertrophy. Results form the Swed
•   Nyström F, Malmqvist K, Ohman KP, Kahan T
  Nurse-recorded and ambulatory blood pressure predicts treatment-induced reduction of left ventricular hypertrophy equally well in hypertension: results from the Swedish irbesartan left ventricular hypertrophy inv

Randomized, Double-blind Evaluation of the Effects of Irbesartan and Atenolol on Cardiovascular Structure and Function in Subjects With Hypertension and Left Ventricular Hypertrophy

Details for clinical trial NCT00389168